Malkevitch Nina, Rohne Daniela, Pinczewski Joel, Aldrich Kristine, Kalyanaraman V S, Letvin Norman L, Robert-Guroff Marjorie
Basic Research Laboratory, National Cancer Institute, Bethesda, Maryland 20892, USA.
AIDS Res Hum Retroviruses. 2004 Feb;20(2):235-44. doi: 10.1089/088922204773004969.
Combination vaccine regimens in which priming with recombinant DNA is followed by boosting with recombinant viral vectors have been shown in previous studies to effectively enhance cellular immunity. However, no information exists concerning possible synergy of the cellular immune response when DNA immunization is followed by administration of a recombinant vector able to replicate. As our approach makes use of replication-competent Ad HIV and SIV recombinants, we performed a pilot experiment in six rhesus macaques in which we compared immunogenicity resulting from priming with one or two DNA recombinants encoding the SIVsmH4 env and rev genes with that elicited by a single replication-competent Ad5hr-SIV env/rev priming immunization. All macaques were subsequently administered an Ad5hr-SIV env/rev booster immunization followed by two immunizations with SIV gp120 protein. The choice of the env gene as target immunogen allowed comparison of induced cellular immune responses as well as binding and neutralizing antibodies elicited in serum and mucosal secretions. We report here that all immunized monkeys developed strong cellular immunity to the SIV envelope as shown by secretion of interferon-gamma, lysis of envelope-expressing target cells, and/or proliferation in response to gp120 or inactivated SIV. Similarly, all macaques developed anti-gp120 binding antibodies and neutralizing antibodies in serum and IgG and IgA binding antibodies in mucosal secretions. We did not observe consistently enhanced immune responses in any immunization group. We conclude that two sequential immunizations with the same replication-competent Ad5hr-SIV recombinant is as effective as priming with one or two recombinant DNA vaccines followed by a single Ad5hrSIV recombinant immunization.
在先前的研究中已表明,先用重组DNA进行初免,随后用重组病毒载体进行加强免疫的联合疫苗方案可有效增强细胞免疫。然而,关于DNA免疫后给予能够复制的重组载体时细胞免疫反应可能存在的协同作用,尚无相关信息。由于我们的方法使用了具有复制能力的腺病毒(Ad)HIV和SIV重组体,我们在6只恒河猴中进行了一项初步实验,比较了用一种或两种编码SIVsmH4 env和rev基因的DNA重组体进行初免与用单一具有复制能力的Ad5hr-SIV env/rev初免免疫所产生的免疫原性。所有恒河猴随后均接受了Ad5hr-SIV env/rev加强免疫,接着用SIV gp120蛋白进行了两次免疫。选择env基因作为目标免疫原,可比较诱导的细胞免疫反应以及血清和黏膜分泌物中产生的结合抗体和中和抗体。我们在此报告,所有免疫的猴子都对SIV包膜产生了强烈的细胞免疫,这表现为γ干扰素的分泌、包膜表达靶细胞的裂解和/或对gp120或灭活SIV的增殖反应。同样,所有恒河猴在血清中都产生了抗gp120结合抗体和中和抗体,在黏膜分泌物中产生了IgG和IgA结合抗体。我们在任何免疫组中均未观察到持续增强的免疫反应。我们得出结论,用相同的具有复制能力的Ad5hr-SIV重组体进行两次序贯免疫与先用一种或两种重组DNA疫苗进行初免,随后用单一Ad5hr-SIV重组体免疫一样有效。